Blood test to detect early endometrial cancer in women in China
Studies a blood test to find endometrial cancer early in women.
Plain-language title generated from the registry record
Registry title: Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
Key facts
- Where
- Guiyang, ChinaSee the site
Where in China
- Guizhou Provincial People's HospitalGuiyang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guizhou Provincial People's Hospital
- Trial code
- NCT07892755
- Record updated
- 23 October 2026
- Original description
Endometrial cancer is one of the most common gynecological malignancies, and its incidence is rising. Currently, there is a lack of highly effective and non-invasive screening methods. Liquid biopsy, which analyzes cell-free DNA (cfDNA) in the blood, has emerged as a promising approach for early cancer detection. This observational study aims to develop and evaluate a non-invasive blood test to screen for early-stage endometrial cancer and to distinguish between benign and malignant endometrial lesions.Read full original descriptionShow less
Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
Endometrial cancer is one of the most common gynecological malignancies, and its incidence is rising. Currently, there is a lack of highly effective and non-invasive screening methods. Liquid biopsy, which analyzes cell-free DNA (cfDNA) in the blood, has emerged as a promising approach for early cancer detection. This observational study aims to develop and evaluate a non-invasive blood test to screen for early-stage endometrial cancer and to distinguish between benign and malignant endometrial lesions.
This study plans to enroll 512 female participants, divided into three groups: 216 patients with stage I-IV endometrial cancer, 80 patients with atypical endometrial hyperplasia (a precancerous condition), and 216 healthy controls. We will collect peripheral blood samples from all participants and perform low-pass whole-genome sequencing (WGS) on the extracted plasma cfDNA. By analyzing specific DNA features (such as DNA fragment patterns, end motifs, and copy number variations) and using artificial intelligence (machine learning), we will build a predictive model. This study hopes to establish a more effective, non-invasive early screening strategy to improve the clinical diagnosis of endometrial cancer in the Chinese population.
Inclusion: Female, aged > 18 years; Participants fully understand the study requirements and sign the written informed consent; Cohort A (Endometrial Cancer): Patients with histologically and/or cytologically confirmed stage I-IV endometrial cancer; comprehensive clinical and pathological information is available; Cohort B (Atypical Hyperplasia): Patients diagnosed with atypical endometrial hyperplasia; comprehensive clinical and pathological information is available; Cohort C (Healthy Control): Healthy female subjects with no tumors or suspicious nodules confirmed by systematic examination.
Exclusion: Pregnant women; Current diagnosis of tumors other than endometrial cancer or a history of previous tumors; Received any form of tumor treatment prior to blood draw, including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy, or immunotherapy; Current febrile illness, or acute/inflammatory disease requiring internal medical treatment within 14 days prior to blood draw; Organ transplant recipients or previous recipients of allogeneic bone marrow or stem cell transplants; Poor health status or unsuitable for blood draw; Any other clinically significant disease or condition that, in the investigator's opinion, may affect protocol compliance, affect the subject's ability to sign informed consent, or make the subject unsuitable for this clinical study.